Freedom Day Solutions LLC Raises Position in Novo Nordisk A/S (NYSE:NVO)

Freedom Day Solutions LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 24,750 shares of the company’s stock after acquiring an additional 420 shares during the quarter. Freedom Day Solutions LLC’s holdings in Novo Nordisk A/S were worth $2,129,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in NVO. OLD National Bancorp IN raised its position in Novo Nordisk A/S by 30.5% in the 3rd quarter. OLD National Bancorp IN now owns 4,399 shares of the company’s stock worth $524,000 after purchasing an additional 1,027 shares during the period. Ledyard National Bank grew its holdings in Novo Nordisk A/S by 6.2% in the 3rd quarter. Ledyard National Bank now owns 4,285 shares of the company’s stock worth $510,000 after acquiring an additional 250 shares during the last quarter. Waldron Private Wealth LLC grew its holdings in Novo Nordisk A/S by 44.8% in the 3rd quarter. Waldron Private Wealth LLC now owns 4,141 shares of the company’s stock worth $493,000 after acquiring an additional 1,282 shares during the last quarter. Stanley Laman Group Ltd. bought a new stake in Novo Nordisk A/S in the 3rd quarter worth $282,000. Finally, Weaver Capital Management LLC grew its holdings in Novo Nordisk A/S by 15.3% in the 3rd quarter. Weaver Capital Management LLC now owns 2,298 shares of the company’s stock worth $274,000 after acquiring an additional 305 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Up 1.3 %

Shares of NYSE NVO opened at $83.38 on Thursday. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The stock has a market cap of $374.18 billion, a P/E ratio of 25.34, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45. The firm has a 50-day moving average of $86.89 and a 200 day moving average of $108.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.